The Medicines Company reported revenue results for the first quarter of 2016. For the quarter, net revenue totaled $50.3 million, which includes $18.9 million of royalty revenue from the authorized generic sales of Angiomax by Sandoz. Revenues are down 54% year-on-year, driven mainly by loss of exclusivity in 2015 for Angiomax.

For 2016, the company now anticipates net revenue to be $160 million to $170 million. The GAAP estimate includes intangible amortization of approximately $26 million, mainly for product rights.